newsfilter
← Latest News
Business Wire·

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • Immunome Inc. granted inducement awards on November 2, 2026 to seventeen new employees under its 2024 Inducement Plan.
  • The awards consist of 206,700 non-statutory stock options & 103,350 restricted stock units (RSUs).
  • Stock options have an exercise price of $19.59 per share based on the closing price on November 2, 2026.
  • Stock options vest over four years with 25% vesting on the first anniversary & the remainder monthly over 36 months.
  • RSUs vest over four years with 25% vesting on each anniversary of the commencement date.
  • Vesting for both award types is contingent on continued employment through the applicable dates.
  • Immunome is advancing therapies including varegacestat, IM-1021, IM-1617, IM-3050, & IM-1340.